Oral Session 1-12D CLL

[OS1-12D-6] Outcomes of standard of care regimens in treatment-naive CLL patients with unmutated IGHV genes

Paolo Ghia¹, Peter Hillmen², Carol Moreno³, Stephan Stilgenbauer⁴, Thomas Webb⁵, Anil Lohnde⁶, Angela Howes⁵, Michelle Mahler⁶, Nishan Sengupta⁶, Mark Wildgust⁶ (1.Universita Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italian Republic, 2.The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, United Kingdom of Great Britain and Northern Ireland, 3.Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4.Department of Internal Medicine, Division of Hematology, University of Ulm, Ulm, Federal Republic of Germany, 5.Janssen Research & Development, High Wycombe, United Kingdom of Great Britain and Northern Ireland, 6.Janssen Research and Development, Raritan, United States of America)